Clinical Trial Search

Primary: Number of Participants With Overall Response (OR) for Cycle 1 (Including the Redosing Cycle), as Assessed by the Investigator — 7; 15 participants

Primary: Objective Response (OR) Determined by the Independent Review Facility — 30.3; 42.9 Percentage of participants — p=0.0011

Primary: Duration of Mechanical Ventilation Through 14 Days — 4.0; 4.5 days

Primary: Progression-free Survival (PFS) — 7.5; 5.8 Months

Primary: Change in Restless Legs Syndrome Rating Scale — -5.0; -1.0; -2.7; -5.0 RLS Rating Score

Primary: Blood Pressure and Heart Rates;

Primary: Percentage of Participants With Objective Response (OR; Using Response Evaluation Criteria in Solid Tumors [RECIST]) — 30.0; 35.9 percentage of participants

Primary: Pain Scores Assessed by Neonatal Facial Action — 14; 18; 30; 44 Percentage of time — p=< 0.05

Primary: Progression Free Survival (PFS) — 5.72; 6.87; 7.59; 6.44 Months — p=0.8268

Primary: Objective Response Rate as Measured by RECIST Criteria After Every 2 Courses of Treatment for up to 6 Courses — 2 participants

Primary: Composite Score of Plaque Inflammation/Stability Gene Expression as Assayed by Ribonucleic Acid (RNA) Taqman Analysis — 1.36; 0.82 Cycle threshold (Ct) — p=0.811

Primary: Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation — -0.53; 0.03 log10 copies/mL

Primary: Conners' Adult ADHD Rating Scales (CAARS™) — -12; -8.93 units on a scale — p=0.0093

Primary: Number of Participants Who Received the Therapeutic Dose at the Seven Clinical Research Sites — 7; 8; 8; 5 participants

Primary: The Primary Efficacy Endpoint of This Study is the Incidence of Cold Illnesses. — 47.1; 43.9 cold illnesses per 100 subjects — p=>0.5000